


**REMARKS**

This Preliminary Amendment is being made upon entry of International Application No. PCT/US03/09450 into the U.S. National Phase of prosecution.

In the specification, a new paragraph has been added to the first line of the specification to include the priority information. An Abstract on a separate sheet is attached as required under 37 CFR 1.72(b).

Claims 1-48 have been cancelled without prejudice or disclaimer. Support for claims 49-91 may be found in original claims 1-48. Further support for claims 49 and 73 may be found in the specification at page 24, lines 14-15. Support for claims 57 and 77 may be found at page 24, lines 1-2.

Respectfully submitted,




Kathryn L. Sieburth  
Attorney for Applicants  
Registration No. 40,072

GLAXOSMITHKLINE  
Corporate Intellectual Property UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-5012  
Facsimile (610) 270-5090

N:\kls\cases\p51328\natl Stage\preliminary amendment.doc

# ABSTRACT OF THE DISCLOSURE

Disclosed is a compound having the formula:



pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts and solvates of this invention are useful as LXR agonists.